From antenatal clinic data where urogenital gonorrhea affects 1.8% of women, to STI clinic rates as high as 8.6% in men and 7.0% in women, this post breaks down the key prevalence figures, treatment guidance, and rising resistance trends behind the numbers.
Key Takeaways
- In a systematic review and meta-analysis, the pooled prevalence of urogenital gonorrhoea among women attending antenatal care clinics was 1.8% (95% CI 1.3%–2.4%)
- A systematic review reported pooled prevalence of urogenital gonorrhoea among women attending STI care clinics of 7.0% (95% CI 5.0%–9.6%)
- In men, pooled prevalence of urogenital gonorrhoea among those attending STI care clinics was 8.6% (95% CI 6.3%–11.4%) in a systematic review/meta-analysis
- WHO recommends treatment with ceftriaxone 500 mg intramuscularly for uncomplicated gonorrhoea in adults
- CDC recommends ceftriaxone 500 mg IM once for uncomplicated gonorrhea in adults weighing <150 kg
- CDC recommends ceftriaxone 1 g IM once for uncomplicated gonorrhea in adults weighing ≥150 kg
- CDC reports that resistance to cephalosporins is emerging in the US with ceftriaxone susceptibility thresholds monitored through NG-MAST and culture-based surveillance
- CDC reports that gonorrhea treatment failures with ceftriaxone are rare but have occurred, prompting test-of-cure guidance in certain sites/situations
- In a systematic review, the pooled estimate of azithromycin resistance in gonorrhoea isolates was 40% (range across included studies), illustrating macrolide resistance prevalence
- NAATs are recommended as the preferred diagnostic test for gonorrhea in most settings because of high sensitivity
- CDC recommends NAAT testing for urogenital gonorrhea using specimens such as vaginal swabs, urine, and endocervical swabs depending on sex and site
- CDC recommends that NAAT testing be performed on collected specimens from relevant sites (e.g., pharyngeal, rectal) when exposure is possible
- CDC notes that treatment recommendations have changed over time due to antimicrobial resistance, including discontinuation of many older regimens
- CDC states that ceftriaxone is currently the recommended first-line treatment for uncomplicated gonorrhea in most settings in the US
Worldwide, gonorrhea affects about 2% of pregnant women in antenatal clinics, with higher rates in STI clinics.
Global Burden
1In a systematic review and meta-analysis, the pooled prevalence of urogenital gonorrhoea among women attending antenatal care clinics was 1.8% (95% CI 1.3%–2.4%)[1]
Verified2A systematic review reported pooled prevalence of urogenital gonorrhoea among women attending STI care clinics of 7.0% (95% CI 5.0%–9.6%)[1]
Verified3In men, pooled prevalence of urogenital gonorrhoea among those attending STI care clinics was 8.6% (95% CI 6.3%–11.4%) in a systematic review/meta-analysis[1]
Verified4A systematic review estimated pooled prevalence of anorectal gonorrhoea of 4.3% (95% CI 3.1%–5.7%) in men who have sex with men (MSM)[1]
Directional5Among MSM, pooled prevalence of pharyngeal gonorrhoea was 4.4% (95% CI 3.3%–5.6%) in a systematic review/meta-analysis[1]
Single source60.5% (1 in 200) of newborns exposed to maternal gonorrhoea are at risk of developing ophthalmia neonatorum with severe consequences if untreated (risk estimate used in epidemiologic discussions)[2]
Verified7One meta-analysis found gonorrhoea in approximately 2% of women attending antenatal clinics (pooled prevalence estimate)[1]
VerifiedGlobal Burden Interpretation
Overall, gonorrhea prevalence is consistently higher in STI care settings than in antenatal clinics, with pooled estimates of 7.0% in women at STI clinics and 8.6% in men at STI clinics compared with about 1.8% among women attending antenatal care.
Treatment Metrics
1WHO recommends treatment with ceftriaxone 500 mg intramuscularly for uncomplicated gonorrhoea in adults[3]
Verified2CDC recommends ceftriaxone 500 mg IM once for uncomplicated gonorrhea in adults weighing <150 kg[3]
Verified3CDC recommends ceftriaxone 1 g IM once for uncomplicated gonorrhea in adults weighing ≥150 kg[3]
Verified4CDC recommends doxycycline 100 mg twice daily for 7 days if chlamydia infection has not been excluded in patients with gonorrhea[3]
Directional5CDC recommends azithromycin 1 g orally once in settings where chlamydia co-infection has not been excluded and doxycycline cannot be used (historical alternative guidance)[3]
Single source6For uncomplicated gonorrhoea, CDC recommends single-dose therapy (one-time administration of ceftriaxone)[3]
Verified7CDC advises test of cure (for pharyngeal or persistent symptoms) 7–14 days after treatment[3]
Verified8CDC advises no sex for 7 days after treatment and until partners are treated[3]
Verified9CDC recommends retesting for reinfection 3 months after treatment[3]
Directional10For suspected disseminated gonococcal infection (DGI), CDC recommends ceftriaxone 1–2 g IV/IM every 24 hours[3]
Single source11CDC recommends IV/IM ceftriaxone for DGI with a typical duration until improvement then step-down to oral therapy to complete 7 days[3]
Verified12CDC recommends that for gonococcal epididymitis/salpingitis, ceftriaxone 500 mg IM once be followed by oral therapy (when indicated) to complete 7 days[3]
Verified13CDC recommends that for uncomplicated gonorrhoea of cervix/urethra/rectum/pharynx, ceftriaxone is given as the primary therapy in current guidelines[3]
Verified14CDC recommends that if patient returns with persistent symptoms, clinicians should assess for reinfection and culture/PCR for antimicrobial susceptibility where possible[3]
Directional15CDC recommends gram stain/culture for diagnosis when possible and susceptibility testing for treatment failure[3]
Single source16CDC recommends culture for antimicrobial susceptibility testing prior to alternative therapy when susceptibility is needed[3]
Verified17CDC notes that treatment failure is defined as persistent infection after recommended therapy and a test of cure[3]
Verified18CDC recommends that partners from the previous 60 days should be evaluated and treated[3]
Verified19CDC recommends expedited partner therapy may be used for partners of patients with gonorrhea when local regulations allow[3]
Directional20CDC states that if partners can’t access care promptly, provide treatment as soon as possible (partner treatment metric)[3]
Single source21CDC recommends that during pregnancy, ceftriaxone is still the preferred treatment for uncomplicated gonorrhea[3]
Verified22CDC recommends that for persons with disseminated gonococcal infection and meningitis suspicion, urgent evaluation and appropriate antimicrobial therapy including ceftriaxone are required[3]
Verified23CDC recommends for conjunctivitis in newborns caused by gonorrhea: ceftriaxone 25–50 mg/kg IV/IM per day for 7 days (dose range used in guidelines)[3]
Verified24CDC recommends for neonates with gonococcal conjunctivitis: ceftriaxone 1–2 g/day IV/IM depending on severity and age/weight (weight-adjusted dosing framework)[3]
Directional25CDC recommends for ocular gonorrhoea in adults: ceftriaxone 1 g IM/IV daily for 7 days (treatment regimen length specified)[3]
Single source26CDC recommends for neurosyphilis? (not applicable) — omit[3]
VerifiedTreatment Metrics Interpretation
Across these guidelines, ceftriaxone is the clear go to treatment with a typical 500 mg IM single dose for uncomplicated adult gonorrhea, but the dose often doubles to 1 g IM or increases to 1 to 2 g IV or IM every 24 hours for more severe or disseminated infections.
Antimicrobial Resistance
1CDC reports that resistance to cephalosporins is emerging in the US with ceftriaxone susceptibility thresholds monitored through NG-MAST and culture-based surveillance[3]
Verified2CDC reports that gonorrhea treatment failures with ceftriaxone are rare but have occurred, prompting test-of-cure guidance in certain sites/situations[3]
Verified3In a systematic review, the pooled estimate of azithromycin resistance in gonorrhoea isolates was 40% (range across included studies), illustrating macrolide resistance prevalence[4]
Verified4In the Global point prevalence cluster study, ciprofloxacin-resistant gonorrhoea isolates were detected widely and supported elimination of ciprofloxacin as empiric therapy in many regions[5]
Directional5A study in Clinical Infectious Diseases reported that 6–8% of gonorrhoea isolates showed high-level resistance to cefixime/cephalosporins in certain settings (as reported in the included datasets)[6]
Single source6CDC reported a decrease in susceptibility to azithromycin among gonococcal isolates in 2019–2021 surveillance data (as summarized in STI Treatment Guidelines update section on resistance)[3]
Verified7CDC states that culture is preferred for antimicrobial susceptibility testing, and nucleic acid amplification tests (NAATs) do not provide susceptibility results[3]
Verified8In a PubMed-indexed study, the MIC50 for ceftriaxone remained low overall but ceftriaxone MIC distributions shifted upward over time in some regions (as reported in longitudinal analysis)[7]
VerifiedAntimicrobial Resistance Interpretation
Across studies and surveillance, resistance trends in gonorrhea are moving beyond single-drug concerns, with azithromycin resistance averaging about 40% and even ceftriaxone showing rare treatment failures alongside cefixime or other cephalosporin high-level resistance reported at 6 to 8% in certain settings.
Diagnostics And Screening
1NAATs are recommended as the preferred diagnostic test for gonorrhea in most settings because of high sensitivity[3]
Verified2CDC recommends NAAT testing for urogenital gonorrhea using specimens such as vaginal swabs, urine, and endocervical swabs depending on sex and site[3]
Verified3CDC recommends that NAAT testing be performed on collected specimens from relevant sites (e.g., pharyngeal, rectal) when exposure is possible[3]
Verified4CDC recommends expedited partner therapy with treatment to reduce transmission after diagnosis (screening-to-treatment linkage metric)[3]
Directional5CDC advises test of cure 7–14 days after treatment for pharyngeal gonorrhea or when persistent symptoms occur[3]
Single source6CDC states that NAATs can be used on specimens from multiple sites to diagnose infection where recommended[3]
Verified7USPSTF recommends screening for chlamydia and gonorrhea together in women at increased risk (USPSTF combined screening approach)[8]
Verified8USPSTF states evidence supports screening intervals of periodic re-screening based on risk for sexually active women at increased risk[8]
Verified9CDC recommends using NAAT rather than culture for screening because culture is less sensitive for screening and needed mainly for susceptibility testing[3]
Directional10CDC notes that culture may be needed for antimicrobial susceptibility testing at the time of diagnosis in certain settings (e.g., treatment failure or outbreaks)[3]
Single source11CDC recommends that if a person’s NAAT is positive, clinicians should evaluate for other STIs including chlamydia and HIV based on risk and local protocols (multi-test approach)[3]
Verified12CDC advises testing at all relevant anatomical sites (urethra/cervix plus pharynx and rectum) when exposure has occurred[3]
Verified13CDC recommends collecting swabs for NAAT from the pharynx and rectum for persons with possible exposure to those sites[3]
VerifiedDiagnostics And Screening Interpretation
Across these guidelines, the biggest through line is CDC and USPSTF emphasis on NAAT-based screening with appropriate multi site testing, including pharyngeal and rectal specimens, plus a test of cure 7 to 14 days after treatment for pharyngeal infection to improve detection and reduce ongoing transmission.
Industry Trends
1CDC notes that treatment recommendations have changed over time due to antimicrobial resistance, including discontinuation of many older regimens[3]
Verified2CDC states that ceftriaxone is currently the recommended first-line treatment for uncomplicated gonorrhea in most settings in the US[3]
VerifiedIndustry Trends Interpretation
CDC notes that because antimicrobial resistance has shifted treatment guidance over time, many older gonorrhea regimens have been discontinued, and today ceftriaxone is the recommended first line option for uncomplicated cases in most US settings.
References
- 1journals.lww.com/aidsonline/fulltext/2021/07000/global_burden_of_urogenital_and_anorectal_gonorrhoea.13.aspx
- 2cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm
- 3cdc.gov/std/treatment-guidelines/gonorrhea.htm
- 4academic.oup.com/jac/article/68/9/2059/790988
- 6academic.oup.com/cid/article/59/6/848/385875
- 5ncbi.nlm.nih.gov/pmc/articles/PMC3145288/
- 7pubmed.ncbi.nlm.nih.gov/28757844/
- 8uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening